Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | EED | O75530 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30109340 | 0.96 | LIPE (0.58) | LIPENPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL30109397 | 0.84 | LIPE (0.51) | LIPENPC1NAMPTALDH1A1KMT2A | |
| SCHEMBL6379837 | 0.84 | MAOB (0.61) | ALDH1A1KMT2AMEN1LMNAHTT | |
| SCHEMBL6380662 | 0.83 | MEN1 (0.54) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL30109408 | 0.82 | ALDH1A1 (0.54) | LIPENPC1RAB9AALDH1A1EED | |
| SCHEMBL17869278 | 0.82 | NPC1 (0.58) | LIPENPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL28459399 | 0.80 | RAB9A (0.79) | NPC1RAB9ANAMPTALDH1A1KMT2A | |
| SCHEMBL14158144 | 0.80 | ESR1 (0.54) | LIPENPC1RAB9AALDH1A1 | |
| SCHEMBL16061897 | 0.79 | MEN1 (0.57) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL30109424 | 0.79 | MEN1 (0.57) | NPC1RAB9AALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | NGLY1, ARG1, ERG28 | LIPE 1489/4885NPC1 705/4885RAB9A 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.